

Summary of the financial delegations and authorizations

Financial authorizations in force Use by the Board of Directors

Nature of the delegations of authority and authorizations granted to the Board by the General Meeting	Maximum authorization amount (in euros)	Grant date of the authorization	Authorization expiration date	Duration	Use by the Board of Directors	Comments
Capital increase through an issue of shares and/or other securities giving access to the Company's share capital						
Share capital increase with PSR	€395 million (nominal amount and gross amount) (Independent cap)	January 8, 2026 (8 th resolution)	March 8, 2028	26 months	April 2, 2026 (€391,780,753.76) Subscription of 1,939,508,682 new shares, at a subscription price per share of €0.202, of which €0.02 of nominal value and €0.182 of issue premium.	May not be used during a public offering
Issuance of ordinary shares of the Company, without PSR reserved to the benefit of Bpifrance Participations	€334,494.54 (nominal amount) €45,992,999.25 (gross amount)	January 8, 2026 (2 nd and 3 rd resolution)	July 8, 2027	18 months	March 6, 2026 (€334,494.54) Issuance of 16,724,727 new ordinary shares with a nominal value of €0.02 each, at an issue price of €2.75 per share, including a €2.73 premium per new ordinary share, representing a capital increase totaling €45,992,999.25.	-
Issuance of ordinary shares of the Company, without PSR reserved to the benefit of Crédit Agricole S.A.	€218,450.90 (nominal amount) €30,036,998.75 (gross amount)	January 8, 2026 (4 th and 5 th resolution)	July 8, 2027	18 months	March 6, 2026 (€218,450.90) Issuance of 10,922,545 new ordinary shares with a nominal value of €0.02 each, at an issue price of €2.75 per share, including a €2.73 premium per new ordinary share, representing a capital increase totaling €30,036,998.75.	-
Issuance of ordinary shares of the Company, without PSR reserved to the benefit of BNP Paribas	€232,800 (nominal amount) €32,010,000 (gross amount)	January 8, 2026 (6 th and 7 th resolution)	July 8, 2027	18 months	March 6, 2026 (€232,800) Issuance of 11,640,000 new ordinary shares with a nominal value of €0.02 each, at an issue price of €2.75 per share, including a €2.73 premium per new ordinary share, representing a capital increase totaling €32,010,800.	-
Share capital increase without PSR through public offering other than those mentioned in article L. 411-2 1° of the French Monetary and Financial Code	10% of the share capital* ^{1,2}	June 5, 2025 (21 st resolution)	August 5, 2027	26 months	-	May not be used during a public offering
Share capital increase without PSR through public offering mentioned in article L. 411-2 1° of the French Monetary and Financial Code	10% of the share capital per 12-month period* ^{1,2}	June 5, 2025 (22 nd resolution)	August 5, 2027	26 months	-	May not be used during a public offering
Increase in the number of securities in case of share capital increase with or without PSR	15% of the initial issue ^{1,2,3}	June 5, 2025 (23 rd resolution)	August 5, 2027	26 months	-	May not be used during a public offering
Authorization to issue shares or securities giving access to the capital without PSR as consideration for contributions in kind of equity securities or securities giving access to the capital	10% of the share capital* ²	June 5, 2025 (24 th resolution)	August 5, 2027	26 months	-	May not be used during a public offering
Share capital increase through incorporation of premiums, reserves, benefits or other	€500 million ⁴	June 5, 2025 (25 th resolution)	August 5, 2027	26 months	January 22, 2025 (€2,491.52) ⁶ June 9, 2025 (€266,928.56) ⁶	-

Financial authorizations in force

Use by the Board of Directors

Nature of the delegations of authority and authorizations granted to the Board by the General Meeting	Maximum authorization amount (in euros)	Grant date of the authorization	Authorization expiration date	Duration	Use by the Board of Directors	Comments
Share purchase program						
Authorization to the Board of Directors for the purpose of purchasing, holding or transferring shares of the Company	10% of the share capital Maximum purchase price per share: € 60	June 5, 2025 (18 th resolution)	December 5, 2026	18 months	Under the share purchase program: - 3,000,000 shares were acquired in 2025 at an average price of € 6.68 Under the liquidity contract: - 11,416,286 shares acquired at an average price of €3.894 - 11,416,286 shares sold at an average price of €3.876	May not be used during a public offering
Capital reduction through the cancellation of treasury shares	10% of the share capital per 24-months period	June 5, 2025 (19 th resolution)	August 5, 2027	26 months	-	-
Reverse share split						
Reverse share split of the Company's shares by allocation of one (1) new share with a par value of €0.80 for forty (40) existing shares with a par value of €0.02 each	N/A	January 8, 2026 (10 th resolution)	N/A	N/A	- ⁸	-
Operations reserved for employees and Company Officers						
Capital increase reserved to employees and executive officers of the Group	2.5% of the share capital** ⁵	January 8, 2026 (11 th resolution)	July 8, 2027	18 months	-	-
Capital increase with the cancellation of the PSR to the benefit of members of a company or group savings plan as employees and/or executive officers of the Company and its affiliated companies	2.5% of the share capital** ⁵	January 8, 2026 (12 th resolution)	March 8, 2028	26 months	-	-
Authorization to grant free shares to employees and Company Officers	1% of the share capital (with a sub-cap of 0.04% of the share capital for the executive corporate officers)* ⁶	June 5, 2025 (28 th resolution)	August 5, 2028	38 months	3,861,723 performance shares were allocated to 743 beneficiaries ⁷	-

* Share capital as at the AGM of June 5, 2025.

** Share capital as at the EGM of January 8, 2026.

¹ Global cap for share capital increases carried out without PSR under resolutions 21st to 24th of the 2025 Shareholders' General Meeting. Any share capital increase pursuant to these resolutions shall be deducted from this aggregate cap of 50%. The maximum nominal amount of the debt securities or other securities giving access to the share capital of the Company carried out under resolutions 21st and 22nd shall not exceed € 1.5 billion or counter value of this amount in the event of an issue in a different currency.

² Global cap for share capital increases without PSR carried out under resolutions 21st to 24th of the 2025 Shareholders' General Meeting. Any share capital increase carried out pursuant to these resolutions shall be deducted from this 10% aggregate cap and the aggregate amount of 50% provided by resolution 9th of the 2026 Shareholders' General Meeting.

³ The nominal amount of the capital increases pursuant to resolution 23rd of the 2025 Shareholders' General Meeting shall be deducted from (i) the cap of the resolution pursuant to which the initial issuance was decided, (ii) the aggregate cap set by resolution 9th of the 2026 Shareholders' General Meeting, and (iii) in case of share capital increase without PSR, the amount of the sub-cap mentioned in resolution 21st of the 2025 Shareholders' General Meeting.

⁴ Autonomous, non deductible cap from the overall cap provided for in resolution 20th of the 2025 Shareholders' General Meeting, nor from the sub-cap provided for in resolution 21st of the 2025 Shareholders' General Meeting.

⁵ Common cap for capital increases carried out under the 11th and 12th resolutions adopted by the 2026 Shareholders' General Meeting.

⁶ The total number of allocations of free shares carried out under the 28th resolution of the 2025 Shareholders' General Meeting shall not exceed 1% of the share capital at the date of the 2025 Shareholders' General Meeting.

⁷ Use in the context of the performance share plan which acquisition period expired in 2025 or for the anticipated vesting of the performance shares under particular circumstances (death, invalidity).

⁸ The implementation of the reverse stock split, whereby forty existing shares with a nominal value of €0.02 each will be exchanged for one new share to be issued with a nominal value of €0.80, is taking place from May 14 to June 12, 2026 (inclusive) in accordance with the tenth resolution approved by the Extraordinary General Meeting held on January 8, 2026.